EBMT 2016 | Virus-specific T cells – effectiveness, safety profile and use
Ann Leen
• 4 Apr 2016
Ann Leen, PhD, from Baylor College of Medicine, Houston, TX, US, provides an overview of the safety and effectivness of virus-specific T cells and their use in transplant patients. According to Dr Leen, there is a lot of research focusing around the use of algorithms to help phyisicans choose the right product for their patients and the next step would be a registration trial. She further describes how referrals usually come from transplant physicians. In order to provide the virus-specific T cells to the patients, they require the HLA characteristics of the patient and the details of their infection.
Recorded at the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Valencia, Spain.
